Discovering the anticancer potential of non-oncology drugs by systematic viability profiling

2020/01/20 by Steven M. Corsello, Rohith T. Nagari, Ryan D. Spangler +44 · 3 citations
Medicine · Nursing · #Drug Transport and Resistance Mechanisms #Trace Elements in Health #Tuberculosis Research and Epidemiology

paper · doi:10.1038/s43018-019-0018-6

crossref issued 2020/01/20 · crossref published 2020/01/20 · crossref published-online 2020/01/20 · openalex publication_date 2020/01/20 · crossref created 2020/01/20 · crossref deposited 2022/12/06 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01 · crossref indexed 2026/08/02

Citations

• A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays
• Systematic identification of genomic markers of drug sensitivity in cancer cells
• limma powers differential expression analyses for RNA-sequencing and microarray studies
• Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
• Genetic and transcriptional evolution alters cancer cell line drug response

Cited by

• Artificial Intelligence in Cancer Research and Precision Medicine
• A triple-action PROTAC for wild-type p53 cancer therapy
• Zardaverine [wikipedia]